Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DSGN vs GLUE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DSGN Captures Overall Composite Edge (49.9 HOLD vs 43.5 HOLD), While GLUE Leads 3–2 on Growth & Valuation Pillars
DSGN Overall Winner
6-Pillar Tally: DSGN 2 – 3 GLUE (1 Tie)
Matrix Metrics: DSGN 4 – 6 GLUE
As of Nov 16, 2026, Design Therapeutics, Inc. (DSGN) captures the overall head-to-head institutional edge over Monte Rosa Therapeutics, Inc. (GLUE) on higher Unified Composite conviction (49.9/100 HOLD vs. 43.5/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality, Balance Sheet & Cash Flow), while GLUE wins 3–2 across the 6-pillar growth and valuation breakdown. DSGN trades at $9.94 (N/M Forward P/E, 0.0% operating margin) versus GLUE at $9.11 (10.0x Forward P/E, -214.5% operating margin).
- Growth vs. Quality Trade-Off: DSGN earns the overall head-to-head edge with a stronger Unified Composite Score (49.9/100 HOLD vs. GLUE 43.5/100 HOLD) and 1.32β · 61% Vol risk profile, whereas GLUE leads top-line expansion (+325.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile GLUE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DSGN vs GLUE
DSGN
Head-to-Head Winner
Design Therapeutics, Inc. Common Stock
$9.94
-5.06% 1D
Market Cap
$677.5M
TTM Revenue
$33,000
Forward P/E
N/M
Beta / 30D Vol
1.32β · 61% Vol
Unified Composite Score
49.9
HOLD
Tech 55.0
Fund 56.0
Flow 63.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
GLUE
Monte Rosa Therapeutics, Inc. Common Stock
$9.11
-2.77% 1D
Market Cap
$795.5M
TTM Revenue
$70M
Forward P/E
10.0x
Beta / 30D Vol
0.94β · 53% Vol
Unified Composite Score
43.5
HOLD
Tech 29.0
Fund 52.0
Flow 70.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (DSGN 2 – 3 GLUE)
1. Valuation Multiples
GLUE
Forward P/E
N/M
10.0x
Trailing P/E
N/M
10.0x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
11.2x
2. Growth & Scale
GLUE
Revenue Growth (YoY)
+0.0%
+325.8%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$33,000
$70M
Market Cap
$677.5M
$795.5M
3. Profitability & Quality
DSGN
Gross Margin
N/A
-92.2%
Operating Margin
0.0%
-214.5%
Net Profit Margin
0.0%
-186.2%
Return on Equity (ROE)
-36.9%
-35.3%
4. Balance Sheet & Cash Flow
DSGN
Cash Generation (TTM)
-$59M
-$174M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$13M Net Cash
$8.9M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
GLUE
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
92.0% (13th %ile)
100.8% (16th %ile)
Put/Call OI Skew
N/A
6.27x (Put-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DSGN (4) vs GLUE (6)| Institutional Metric | DSGN | GLUE | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $677.5M | $795.5M | GLUE | |
| Trailing P/E Ratio | N/M | 10.0x | GLUE | |
| Forward P/E Ratio | N/M | 10.0x | GLUE | |
| Revenue Growth (YoY) | +0.0% | +325.8% | GLUE | |
| Operating Margin (TTM) | 0.0% | -214.5% | DSGN | |
| Net Profit Margin | 0.0% | -186.2% | DSGN | |
| Return on Equity (ROE) | -36.9% | -35.3% | GLUE | |
| 52-Week Range Position | 30% ($7–$17) | 1% ($9–$26) | DSGN | |
| Beta / 30D Volatility | 1.32β · 61% Vol | 0.94β · 53% Vol | GLUE | |
| Unified Institutional Score | 49.9 / 100 (HOLD) | 43.5 / 100 (HOLD) | DSGN | |
| Trailing 12M Revenue (USD) | $33,000 | $70M | Scale | |
| Gross Profit Margin (TTM) | N/A | -92.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 11.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$59M ($13M Net Cash) | -$174M ($8.9M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DSGN +2.88 pp
3M Horizon
DSGN +4.48 pp
6M Horizon
DSGN +42.32 pp
1Y Horizon
DSGN +77.17 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DSGN Revenue | GLUE Revenue | DSGN Op. Margin | GLUE Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | $0M | N/A | -3685.8% | N/A | DSGN |
| FY2024 | N/A | $80M | N/A | -107.3% | GLUE |
| FY2025 | N/A | $120M | N/A | -43.8% | GLUE |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DSGN
BREAKDOWN
Current IV
92.0%
IV Percentile
13th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
GLUE
BREAKDOWN
Current IV
100.8%
IV Percentile
16th %ile
Put/Call OI Skew
6.27x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact GLUE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DSGN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
GLUE Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ DSGN vs GLUE Key Questions & Quantitative Answers
As of Nov 16, 2026, Design Therapeutics, Inc. (DSGN) captures the overall head-to-head institutional edge over Monte Rosa Therapeutics, Inc. (GLUE) on higher Unified Composite conviction (49.9/100 HOLD vs. 43.5/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality, Balance Sheet & Cash Flow), while GLUE wins 3–2 across the 6-pillar growth and valuation breakdown. DSGN trades at $9.94 (N/M Forward P/E, 0.0% operating margin) versus GLUE at $9.11 (10.0x Forward P/E, -214.5% operating margin). Growth vs. Quality Trade-Off: DSGN earns the overall head-to-head edge with a stronger Unified Composite Score (49.9/100 HOLD vs. GLUE 43.5/100 HOLD) and 1.32β · 61% Vol risk profile, whereas GLUE leads top-line expansion (+325.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile GLUE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GLUE leads the Growth & Scale pillar: DSGN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with GLUE at +325.8% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (-92.2% gross margin, -214.5% operating margin). Across the 3-period historical trajectory (FY2020 to FY2025), DSGN cumulative revenue shifted N/A while GLUE shifted +50.0%. In operating R&D and SG&A reinvestment, DSGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GLUE.
GLUE screens cheaper on headline valuation multiples. DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas GLUE trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 11.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DSGN (-36.9% ROE) versus GLUE (-35.3% ROE) capital efficiency.
In options market volatility and institutional positioning, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk). By comparison, GLUE carries 100.8% implied volatility (16th %ile, Compressed (<25th %ile)), a 6.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.94β · 53% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
GLUE vs DSGN · Reverse Pair
DSGN vs CGEM
· Sector Peer
DSGN vs EWTX
· Sector Peer
DSGN vs IMCR
· Sector Peer
GLUE vs EWTX
· Sector Peer
GLUE vs ERAS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem